Victory Capital Management Inc. Sells 9,868 Shares of LivaNova PLC (NASDAQ:LIVN)

Victory Capital Management Inc. reduced its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 1.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 925,234 shares of the company's stock after selling 9,868 shares during the period. Victory Capital Management Inc. owned approximately 1.70% of LivaNova worth $42,848,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of LIVN. Point72 Asset Management L.P. grew its position in LivaNova by 62.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock valued at $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Point72 DIFC Ltd lifted its stake in shares of LivaNova by 75,799.6% in the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company's stock worth $9,531,000 after buying an additional 181,161 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of LivaNova by 286.4% during the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company's stock valued at $10,889,000 after buying an additional 153,611 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after acquiring an additional 93,311 shares in the last quarter. Finally, Paradice Investment Management LLC increased its position in shares of LivaNova by 15.3% during the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after acquiring an additional 64,680 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

LIVN has been the topic of several recent analyst reports. Mizuho cut their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Needham & Company LLC lowered their target price on shares of LivaNova from $75.00 to $64.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Barclays dropped their price target on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, LivaNova has a consensus rating of "Moderate Buy" and an average target price of $61.17.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded up $0.09 during midday trading on Wednesday, hitting $39.15. 638,226 shares of the company's stock traded hands, compared to its average volume of 633,547. The firm has a fifty day moving average of $46.47 and a 200 day moving average of $49.25. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 93.21 and a beta of 1.10.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.